Senate’s US FDA User Fee Bill Answers Biosimilar Interchangeable Exclusivity Questions

 
• By Derrick Gingery
  
biologic
The Senate bill would address some biosimilar questions, but others still linger. • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Biosimilars & Generics